{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:01:51Z","timestamp":1791352911009,"version":"4.3.1"},"reference-count":125,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Neurodegener. Dis. Manag."],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.2217\/nmt-2016-0005","type":"journal-article","created":{"date-parts":[[2016,5,27]],"date-time":"2016-05-27T10:05:47Z","timestamp":1464343547000},"page":"249-268","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":48,"title":["Nondopaminergic Treatments for Parkinson\u2019s Disease: Current and Future Prospects"],"prefix":"10.1080","volume":"6","author":[{"given":"Maria Eliza","family":"Freitas","sequence":"first","affiliation":[{"name":"Movement Disorders Clinic Division of Neurology University of Toronto Toronto Western Hospital 399 Bathurst Street MCL7-412\rToronto\rON\rM5T 2S8\rCanada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan H","family":"Fox","sequence":"additional","affiliation":[{"name":"Movement Disorders Clinic Division of Neurology University of Toronto Toronto Western Hospital 399 Bathurst Street MCL7-412\rToronto\rON\rM5T 2S8\rCanada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2016,5,27]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnana.2015.00117"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2014.07.037"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0105-4"},{"key":"e_1_3_2_6_1","first-page":"113","article-title":"Advances in nondopaminergic treatments for Parkinson\u2019s disease","volume":"8","author":"Stayte S","year":"2014","unstructured":"Stayte S , VisselB . Advances in nondopaminergic treatments for Parkinson\u2019s disease . Front Neurosci.8, 113 ( 2014 ).","journal-title":"Front Neurosci."},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25418"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0000000000000073"},{"key":"e_1_3_2_9_1","unstructured":"A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson\u2019s Disease \u2013 ClinicalTrials.gov . https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01968031?term=NCT01968031&rank=1 ."},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2015.2268"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70148-6"},{"key":"e_1_3_2_12_1","unstructured":"Safety and Efficacy Study of Tozadenant to Treat End of Dose Wearing Off in Parkinson\u2019s Patients Using Levodopa \u2013 ClinicalTrials.gov . https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02453386?term=NCT02453386&rank=1 ."},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25751"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25961"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-150569"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26286"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26159"},{"key":"e_1_3_2_18_1","unstructured":"Efficacy and Safety of Amantadine HCl Extended Release Tablets to Treat Parkinson\u2019s Disease Patients With Levodopa Induced Dyskinesia. (ALLAY-LID I) . https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02153645?term=NCT02153645&rank=1 ."},{"key":"e_1_3_2_19_1","unstructured":"Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson\u2019s Disease Subjects With Levodopa-Induced Dyskinesias (ALLAY-LID II) . https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02153632?term=NCT02153632&rank=1 ."},{"key":"e_1_3_2_20_1","unstructured":"Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson\u2019s Disease Patients \u2013 ClinicalTrials.gov . https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01767129?term=NCT01767129&rank=1 ."},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12468"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2014.01.016"},{"key":"e_1_3_2_23_1","unstructured":"Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson\u2019s Disease \u2013 ClinicalTrials.gov . https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01789047?term=NCT01789047&rank=1 ."},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23616"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25561"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2014.05.003"},{"key":"e_1_3_2_27_1","unstructured":"ADX48621 for the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson\u2019s Disease \u2013 ClinicalTrials.gov . https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01336088?term=NCT01336088&rank=1 ."},{"key":"e_1_3_2_28_1","unstructured":"Buspirone in Combination With Amantadine for the Treatment of Levodopa-induced Dyskinesia \u2013 ClinicalTrials.gov . https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02589340?term=NCT02589340&rank=1 ."},{"key":"e_1_3_2_29_1","unstructured":"Buspirone Treatment of Iatrogenic Dyskinesias in Advanced Parkinson\u2019 Disease \u2013 ClinicalTrials.gov . https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02617017?term=NCT02617017&rank=1 ."},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awu409"},{"key":"e_1_3_2_31_1","unstructured":"A Study to Examine the Efficacy and Safety of Eltoprazine HCl for Treatment of Levodopa-induced Dyskinesia in Parkinson\u2019s Disease Patients \u2013 ClinicalTrials.gov . https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02439125?term=NCT02439125&rank=1 ."},{"key":"e_1_3_2_32_1","unstructured":"Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson\u2019s Disease \u2013 ClinicalTrials.gov . https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01474421?term=NCT01474421&rank=1 ."},{"key":"e_1_3_2_33_1","first-page":"340","article-title":"Beneficial effects of nicotine, cotinine and its metabolites as potential agents for Parkinson\u2019s disease","volume":"6","author":"Barreto GE","year":"2014","unstructured":"Barreto GE , IarkovA, MoranVE . Beneficial effects of nicotine, cotinine and its metabolites as potential agents for Parkinson\u2019s disease . Front. Aging Neurosci.6, 340 ( 2014 ).","journal-title":"Front. Aging Neurosci."},{"key":"e_1_3_2_34_1","unstructured":"Study of NP002 in Subjects With Idiopathic Parkinson\u2019s Disease to Treat Dyskinesias Due to Levodopa Therapy \u2013 ClinicalTrials.gov . https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00957918?term=NCT00957918&rank=1 ."},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.5334\/tohm.240"},{"key":"e_1_3_2_36_1","unstructured":"Investigation of the Efficacy and Safety of IncobotulinumtoxinA (Xeomin) in Parkinson\u2019s Tremor: A Customized Approach \u2013 ClinicalTrials.gov . https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02419313?term=NCT02419313&rank=1 ."},{"key":"e_1_3_2_37_1","unstructured":"Use of Kinematic Assessment of Hand Tremor Pre- and Post- Treatment With Botulinum Toxin Type A in Essential Tremor and Parkinson Disease \u2013 ClinicalTrials.gov . https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02427646?term=NCT02427646&rank=1 ."},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182143537"},{"key":"e_1_3_2_39_1","unstructured":"Study to Assess the Clinical Benefit and Safety of Droxidopa in Parkinson\u2019s Disease \u2013 ClinicalTrials.gov . https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02066571?term=NCT02066571&rank=1 ."},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318263570d"},{"key":"e_1_3_2_41_1","unstructured":"Caffeine as a Therapy for Parkinson\u2019s Disease \u2013 ClinicalTrials.gov . https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01738178?term=caffeine+parkinson%27s+disease&rank=3 ."},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62106-6"},{"key":"e_1_3_2_43_1","unstructured":"Cholinesterase Inhibitors to Slow Progression of Visual Hallucinations in Parkinson\u2019s Disease \u2013 ClinicalTrials.gov . https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01856738?term=NCT01856738&rank=1 ."},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000729"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26179"},{"key":"e_1_3_2_46_1","unstructured":"Treatment of Orthostatic Intolerance in Patients With Parkinson\u2019s Disease Using Midodrine \u2013 ClinicalTrials.gov . https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02365012?term=NCT02365012&rank=1 ."},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000615"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26086"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.2147\/VHRM.S53983"},{"key":"e_1_3_2_50_1","unstructured":"Orthostatic Dysregulation and Associated Gastrointestinal Dysfunction in Parkinson\u2019s Disease -Treatment \u2013 ClinicalTrials.gov . https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01993680?term=NCT01993680&rank=1 ."},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181d8c1b7"},{"key":"e_1_3_2_52_1","unstructured":"Study of Glycopyrrolate for Moderate-to-severe Sialorrhea in Parkinson\u2019s Disease (GLYCOPAR) \u2013 ClinicalTrials.gov . https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02382198?term=NCT02382198&rank=1 ."},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxicon.2015.08.014"},{"key":"e_1_3_2_54_1","unstructured":"Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions \u2013 ClinicalTrials.gov . https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02091739?term=NCT02091739&rank=1 ."},{"key":"e_1_3_2_55_1","unstructured":"Efficacy and Safety Study of MYOBLOC\u00ae Followed by Open-Label Multiple-Treatment With MYOBLOC\u00ae in the Treatment of Troublesome Sialorrhea in Adult Subjects \u2013 ClinicalTrials.gov . https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01994109?term=NCT01994109&rank=1 ."},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1002\/gps.4109"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26236"},{"key":"e_1_3_2_58_1","unstructured":"The Efficacy and Safety Study of High Dose Donepezil in Parkinson\u2019s Disease With Dementia \u2013 ClinicalTrials.gov . https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02415062?term=NCT02415062&rank=1 ."},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1159\/000438824"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nurt.2008.05.008"},{"key":"e_1_3_2_61_1","unstructured":"SYN120 a Dual 5-HT6\/5-HT2A Antagonist Proof of Concept Study to Evaluate Its Safety Tolerability and Efficacy in Parkinson\u2019s Disease Dementia (SYNAPSE) \u2013 ClinicalTrials.gov . https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02258152?term=NCT02258152&rank=1 ."},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-014-0511-3"},{"key":"e_1_3_2_63_1","unstructured":"Botulinum A Toxin in Patients With Parkinson\u2019s Disease \u2013 ClinicalTrials.gov . https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00822913?term=NCT00822913&rank=1 ."},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00243-4"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-015-7823-3"},{"key":"e_1_3_2_66_1","unstructured":"Effects of PR Oxycodone and of Levodopa vs Placebo on Central Neuropathic Pain in Parkinson\u2019s Disease \u2013 ClinicalTrials.gov . https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02601586?term=NCT02601586&rank=1 ."},{"key":"e_1_3_2_67_1","unstructured":"The Use of Botox in Advanced Parkinson\u2019s Patients Experiencing Pain \u2013 ClinicalTrials.gov . https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02472210?term=NCT02472210&rank=1 ."},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26362"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tins.2006.09.004"},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12640-013-9446-8"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2011.09.023"},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(11)70012-6"},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70153-X"},{"key":"e_1_3_2_74_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-012-0016-z"},{"key":"e_1_3_2_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2014.11.001"},{"key":"e_1_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70218-0"},{"key":"e_1_3_2_77_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23829"},{"key":"e_1_3_2_78_1","unstructured":"Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia \u2013 ClinicalTrials.gov . https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02274766?term=NCT02274766&rank=1 ."},{"key":"e_1_3_2_79_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0328-z"},{"key":"e_1_3_2_80_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.2012.08243.x"},{"key":"e_1_3_2_81_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26352"},{"key":"e_1_3_2_82_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.54.8.1589"},{"key":"e_1_3_2_83_1","unstructured":"Effects of Talampanel on Patients With Advanced Parkinson\u2019s Disease \u2013 ClinicalTrials.gov . https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00036296?term=NCT00036296&rank=1 ."},{"key":"e_1_3_2_84_1","unstructured":"Talampanel to Treat Parkinson\u2019s Disease \u2013 ClinicalTrials.gov . https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00108667?term=NCT00108667&rank=1 ."},{"key":"e_1_3_2_85_1","unstructured":"Study of LY300164 for the Treatment of Parkinson\u2019s Disease \u2013 ClinicalTrials.gov . https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00004576?term=NCT00004576&rank=1 ."},{"key":"e_1_3_2_86_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22974"},{"key":"e_1_3_2_87_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23983"},{"key":"e_1_3_2_88_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20345"},{"key":"e_1_3_2_89_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23867"},{"key":"e_1_3_2_90_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25920"},{"key":"e_1_3_2_91_1","unstructured":"Open Label Safety Tolerability and Efficacy of AFQ056 in Parkinson\u2019s Patients With L-dopa Induced Dyskinesias \u2013 ClinicalTrials.gov . https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01173731?term=NCT01173731&rank=1 ."},{"key":"e_1_3_2_92_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2014.931370"},{"key":"e_1_3_2_93_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2014-307659"},{"key":"e_1_3_2_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2011.08.004"},{"key":"e_1_3_2_95_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.246"},{"key":"e_1_3_2_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0079-6123(08)00922-9"},{"key":"e_1_3_2_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2015.08.002"},{"key":"e_1_3_2_98_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000110317.52453.6C"},{"key":"e_1_3_2_99_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.2015.1077703"},{"key":"e_1_3_2_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2007.05.002"},{"key":"e_1_3_2_101_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI71640"},{"key":"e_1_3_2_102_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26326"},{"key":"e_1_3_2_103_1","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12314"},{"key":"e_1_3_2_104_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21226"},{"key":"e_1_3_2_105_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26048"},{"key":"e_1_3_2_106_1","first-page":"1","article-title":"Droxidopa in neurogenic orthostatic hypotension","author":"Kaufmann H","year":"2015","unstructured":"Kaufmann H , Norcliffe-KaufmannL, PalmaJ-A . Droxidopa in neurogenic orthostatic hypotension . Expert Rev. Cardiovasc. Ther.1 \u2013 17 ( 2015 ).","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"e_1_3_2_107_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-012-0017-y"},{"key":"e_1_3_2_108_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70106-0"},{"key":"e_1_3_2_109_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10464"},{"key":"e_1_3_2_110_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31825f0451"},{"key":"e_1_3_2_111_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2009.12.048"},{"key":"e_1_3_2_112_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25098"},{"key":"e_1_3_2_113_1","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12386"},{"key":"e_1_3_2_114_1","article-title":"Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson\u2019s disease dementia and cognitive impairment in Parkinson\u2019s disease","volume":"3","author":"Rolinski M","year":"2012","unstructured":"Rolinski M , FoxC, MaidmentI, McShaneR . Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson\u2019s disease dementia and cognitive impairment in Parkinson\u2019s disease . Cochrane Database Syst. Rev.3, CD006504 ( 2012 ).","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_3_2_115_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2011.05.021"},{"key":"e_1_3_2_116_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2014.05.007"},{"key":"e_1_3_2_117_1","doi-asserted-by":"publisher","DOI":"10.1016\/bs.irn.2015.07.005"},{"key":"e_1_3_2_118_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2014.08.013"},{"key":"e_1_3_2_119_1","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-140379"},{"key":"e_1_3_2_120_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23069"},{"key":"e_1_3_2_121_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2015.08.013"},{"key":"e_1_3_2_122_1","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.12061"},{"key":"e_1_3_2_123_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2003.11.065"},{"key":"e_1_3_2_124_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23355"},{"key":"e_1_3_2_125_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23687"},{"key":"e_1_3_2_126_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.111.005678"},{"key":"e_1_3_2_127_1","doi-asserted-by":"publisher","DOI":"10.1007\/7854_2014_310"}],"container-title":["Neurodegenerative Disease Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/nmt-2016-0005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T19:47:54Z","timestamp":1716493674000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/nmt-2016-0005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,27]]},"references-count":125,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["10.2217\/nmt-2016-0005"],"URL":"https:\/\/doi.org\/10.2217\/nmt-2016-0005","relation":{},"ISSN":["1758-2024","1758-2032"],"issn-type":[{"value":"1758-2024","type":"print"},{"value":"1758-2032","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,27]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=inmt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=inmt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2016-01-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-04-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-05-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}